Cost effectiveness of natriuretic peptide measurement in the primary care setting: have we found the gatekeeper for the evaluation of dyspneic outpatients?
Baggish
Aaron L
AL
Cardiology Division and PRIDE Study Group, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Januzzi
James L
JL
D015415:Biomarkers / Q000097:blood; D003362:Cost-Benefit Analysis; D004417:Dyspnea / Q000175:diagnosis; D006333:Heart Failure / Q000175:diagnosis*; D006801:Humans; D008403:Mass Screening / Q000191:economics* / Q000379:methods; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D011320:Primary Health Care / Q000191:economics* / Q000379:methods
D015415:Biomarkers; D020097:Natriuretic Peptide, Brain